Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Furmonertinib 160 mg plus Cisplatin/Pemetrexed in Resectable EGFR-mutated Stage II–IIIB NSCLC
ChiCTR2600116854Phase 2Not yet recruiting
- Sponsor
- Army Medical Center of PLA
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of furmonertinib in non-small cell lung cancer (NSCLC) and EGFR-mutated non-small cell lung cancer, sponsored by Army Medical Center of PLA. Primary endpoint: Major pathologic response rate. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)EGFR-mutated non-small cell lung cancer
Beyond the preview
Go deeper on ChiCTR2600116854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116854.